begin 644 0001564590-20-011806-xbrl.zip
M4$L#!!0 ( )J#7Z-PC!^'[R .ZPHL]D3"5FB??X^3WX^L=L"A[QDJP0&"GA9.4#")WB/P5!A@#&2!%@GQ'H!MT
M!CT8#IZZX:@;C+JAU^\'83^X^CT(1D%04?!/?@90>4;@T@N\T.OUAQ7&+PA_
M1PL")N,*XW".$+Z8#_IQ]^IB@'K#.+X(^K@_') H'@POJTB3="/H8JG ._S>
M0M3GY9PP1C;@GG+$,44,/+J3?@ 3CCUPQQB8&3$)9D02\4PB;ZMU+:.1S#VG
MH\'EB&M]V>JF4W'>>BZ8EXB%'RGAJTU*?,T$-1<1%'>XODV=<$OQN$(0Q"V L+=I6*(_R:8@0&NP(<42SK)2S)B%SMV1"IVCF$1(*D
M"JDE$2@EVJLB^)=2(1(36>TH3CN"F]=$V?O%UK2F=BL3QXR3C2FSJ
M36R)->%@E'\_8<60YT@65M8'_"\]RQT.AT/?4@M F1"ZU1Q#M*76^_9(G!VE
M1HBL\;+>DJ'L"""E!)UGBMPG8C4F,1^9)MAVTQ.1
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M?R(K_2519&JO/8;T]VS2Z#:0M]Y=/74GB8P#X#5_VN<*6!L
M7?O[$OO*,DFBO_BM7:>"2*W$.JHBO64Y)8D1PQEK(5@B.RZWW76!V8N7\].,
MQ,!>3T?;4>#T)=9/19(2H:C.FLH=V"I8"A+?=,S_&-"%\1M#^WO=^#M3K53YUOY=^3V/U!+ P04
M " ":@W-0Q]K-MD4' "43 %0 '-R<'0M,C R,# S,3A?;&%B+GAM
M;,U<:V_;-A3]/F#_@7._K%AE/=*Z<="TR)QD,)8F0>QNQ8:AH"7:)DJ+!B7'
M]K\?J8=CV90LR53-?(FBD.="4_/GQ:S0AX1BS U+]LV6VK!9#O4@_[
MD\O6(C!@X&+< D$(?0\2ZJ/+UAH%K4\??_[IPR^& :YO^_?@R@WQ,[K&@4MH
MLHU\'GU^#K[T]WX [[WTO^;
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M_>6IG\O9-<4(TT<3;ASO#HX0X3%'$%.&QO)YA+',-!%'5\1A=T0Q1AC#8!31\"UY N$\IB("U(0K'%RC
M,5R04!IF%.(>@&/971.1,!!G!%I@B%.&92=7WE<2W/S HU#$;I^,%(@%FT(<
M?KP%;2&C58A\#R57_0TV=??6%:0+"Y#;GM!GTT,X7A,_V%T)/_7MQ@]QN.[Q
M%H1!TN'3W*>^"K4<#)W+"L*W8FU7-#!D2-"V+9
M/T;(X-\4^[_3)UZN,LT5HH%$I_$+H*22EJJ,.,5Y_$$URV!D[)NW)E43[T,B'H_;N"!P#^](>5"TUPMM!&5
M5--37:/TA"987(K]\![.2E\IY7./:9.R6(UU22\T0/",0\2"T:M.R,_FXS38#UF ;$_, 3A0]_#U].1:G@AY4
M23O9=YN=THJKVV)N9HA-L#_Y@]%E..W1V1SZ%>_(0!E(N($@UZ4 RN615A15\YR1_'0EV2J7*G7E-(2KOL=;,#S&\6OI
M=;:"7)!CTI$#VECQ<#Z0)=1LRSB4*EI:/6W30H[-B+K"N/(\OH(@^76'?617
M*PHIP#'*2P ;*X:$Y$UZ(-Y*A<"#K\WV490>6DHU+5-!9%G(),$^C?F=8\WO
MJ%;<^<'F'RZION9WRIK?:<+\BE)QV/S.#S1_CQ\^L"%=^K6LOSU=@=HO<,W;
M7G")VP;!IIGE)4F1&7Y7+0T3(#=[)/W#(>F5>SVZ]WA@CXP^8]^M>!N=AZ%
M]!W,YJV_N65.*37S?UZB9$4@%4_7I,C+(4['0YET**^)1QJ$D/R#Y]4?+,D1
M%$B?06R^&F(ZP/FT>G14F"!9)4ADTS,9\BHHG08E[T44"V0(5G%]=D[-=R)N
M8:AW=K2O"GA-C"Q5F>8IH8NBI)J8*NPH/N)#'J?4K_@:U?Z\>B+NXJBW9L0
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MMD_<\2/Q95?)*1Q_ =3'_P%02P,$% @ FH-S4"^X$OT4!0 R"T !4
M !S7_%N?O6\NN=M&?A[U2VT]:FC:\=S?*= WN]\(6XX44,ERN0*93)?UMBN!>Q"Q>
MML5(JC#A^Q3X'ACZ]P1<"H]+
MLL.%:5M#XXF+:4J1*AQI[;64ZH&QF75\VA$U;E@3]O)'_RWP\X;,"0X1E@,
M_O8(@5-!SCO;&0YHY@#P'W X"%B&DZE@J]2ES\5X1#D'F":K\NX$JJVG:3@\
M?[CW]7( UX(YVX32K"6#L^?ZKDX.H%9)HAD$D*QT5T*APO]ET240W[*0-^ ^
M)$CZK+I*SMBJP+H<\IZ-O$&;,7U6 SD77X5W6SUOJ.L?J%YHZ:O [AKX@7#]
M;X7KYPAW@!?M -(*&ZVCX671ZH21W#VDNJ2*JDM63:M.14Q&IY>;@X82JW
M+CPP?F%JV-?+#=Q]2-48,OD?2L[C":3+"(OE93B/F,@!)+UE&'=7, V80A"\RP
M/7 \/A?=*Z47$ 2"YUP)5.'L6>G%'5')H1(?'9U=ZNTBZL[>V$IB([)K$B
MJ3FXW-M+V-TU6DNX$59@SR83QC?;$",EPX-8UJW)0_1)!8NCAN5[GN\YGF>A
M"&:U6:$V+$CZ4PU@9&1@F\4)= -648H&G56_C\),,,*21M-$\O],QRL?S_@H
M%Y./PQ$IH^6ZR+3LI9.,EYMB\G*D&LAXJ163ES=+N@T[?D[GYAGE%2Z+A[
M8FV5L53H,'QT^9SQ4]!P_,:.2,9-H4/RPE0@?D [N4&3.%CLO']ILS
M>@H=D ^_0"1MU#K\8S4@H:
M:]\ZV)"14]!8>_JP2D910>/O_N&C#257!8V_KTZ*97P4-,07T?(#9LZM
MN\<*K-)>S 'AU1/S90[-?OP/4$L#!!0 ( )J#22Y47:.2^^?I7_Y\_%?#(.>7C28Y
MLQ6_9^=[I.&YW&/DMR^WW\BY;X<#YBEBD+Y20:U0& Z'>:?+
M/>F[H8)Y9-[V!P5B&,G =<$H-I!SJAC1/S5B%:VB42P99J5MF36K6+/,_,%!
MT3PH'OZC6*P5BZD!_ATM@*1^:F0_7\R;^=)!-=7QAMIWM,=(XSS5L=JAU"YW
M*@==Z[!-R"7W
MJ&=SZI)6LM(]((V=)V>N2VX13));)IFX9TX^'K6O@ / !4_6'CK"Y2>Y%-7P
M3=X7O8)5+)8*0$$%$[!Q\S[\O8 L"5!X!"#4/LW%3UCQ"90)D=>7V'(RXC=W-Z>X>!1IF ^@F!#F<
M!F$/=C\; ELR4/+"0;9\.$H4<,D%Z,$$M\< ()Q/P_B>\0C.83P;,6C(P,L.
MA0"S,7-280;@',#=W4ZL:EO2:S&JU6M"M8UE48JY*50O0
MFG2<&7):^;"Y0^58^;CTRY9YN$A=HQYCG"7/PABZFH7?KKZU[#X;4..QCO.'
M>3.8:!#0[*+5G717V?TG70M*4$]V?3'0-A='VC>*EF$=I 8Q@ ?3]B+FR5/C
M5"9/,KV'$/G)YB@MRCF[#R
MI4ILCSN^,SH]=O@]D6KDLI.?M3/
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M49OD?[":B9"YTQ]_@.#UZ+@03$W9\05@HROZ#!=-K(.KRGE>S 9")Y\TS9!C>UCJ^ZZ077H'N3],(,0$3 I[$C08?
MNQ9M=:->]U1P"C.2N&/N])=FHWUQ3EKML_9%ZQ.MJW51_^6VT6YMGQK-K^WKYAXYS]?SL*G:+U?)
MTBO$]50!00Q+C'ZT@#(\QVH5$P V9-PA9DJKXH:%BN6R+@P&U(F?130ZO%BH
M:D_2*J9S3(,7D6]%I4ZH-;OD]R+\E]>W5V1^'%-,QS%)JB$5)2X9OE2,GQ_'
M+5N)>[\2MU8+!,;V]J+9)K<7-]>W[4^TL)M0R!!>$>63%K-UALTL$5\0A&6=TQ<"MW,G-W: D-4SC)$-SH@O8B"U94L$HDVTB
M &S?H:,1(,>\W.D5;'/ZQ*SLZ:SCUGAMS'AI'5U=IFW?]47MA\AII59LE=>I
M\LUNE?DEROS\;7+U+?&/,Q&*8@8@8N!)#J)=F[DN*(:M#^3BYYB/
M^GEJU34:*C]A/^B\2P/):LD?1V3('=4'1PK+UOE7I;,@RB'W6KPP&8%4&X\:
M]2^5\J5R#/$2O4Q+%CY/'L[:0[!>OH 00>>]6PJ<=3TZJ:C[
MSO.]/J;<,3.F6"#\>YP3W?XY<^D0;&B6PS\N*.>=\R_#"VZ"FR_V@@>S7+_D
M+H.>'296S92;AEFN5/<7.+Q5.&EM.;D*)RNSG&S3AT:JY,ISN/F/CD2C-MKTG3
MS^^^KGU]+>J,-Q+I\/Y%VOUN,)O1IXU@]IBUX/G1O9[D2KG%*$]V.=M(::E(
MJ3H;*9TYCF!2QK^^<8^9JT5)EKD/-EQ(15I*,*;FQ4H=00K32YBFX@*\S>(R
M>%LKIJU"#N%)V5P4M&\E:TG),LVY'*K#G]>B[0^]U?A3IX..X$XO8U\<\6>1
M*.W-3^N;&>G/&%4=L5Z+&]B</$5V 0T:M5HS#C2\5=?_#@Y4S
M#:=%RRP_9ZOR_NWMY@*N!5(U0:*B'5G,,,SZ!@+DA0?4)>R!V2&6S\-KB&68
MW"/0Y(:8S"-_\ "([;"8)UGQ34%G!T]GRY8^\)G<)"?^XP\5RSP\DJ3-7!;T
M 2:._/5Y04RE,\$H0>FOD9WY&C1U.(+S[G>[^,;_J*G 6!"S$]"/5G.O;9N82_F"!-?>PC2/P8
MFP30^2X>]7@]YI 6NA+RC4* %!U*;P]_7N/P9S7I7T'87W$!]3ZS[W0!!@T"
MX8.7P(Q8QW\@'>;Z0Y02;$3A(17C9]+E+AI +L%G* 8K<+"N0_)!Z"KJ,3^4
M[HA(V!_+[DA#Q@!^!X0GVC;'!1]B<@P)<1Q()O5&25O7=V%RA,-3"(Y)&%F;
MJ<9[V1G;[,E7,FXDYRA]\?G4,T_#7G "!BMX%-BL;4<>RUV+]7Q&?FF0UF@
MAFK=OPJN (QPUQ4CJE[?$*A7S
MT'&7+),F6U[FD9 '3WJ.#R3S4\>[Z"QMH*77NP);#(.X'T/@7XLK&Q;X";G)
M(*;WK+2;96J85DK@IVH4Q^)>+N:CGEN)?T+BIPY$;P1#"X]?)^E":HPKQ'6W
MN^)^92OY*U;F"F;8*;H_:?/-LF-8.YW=Y?0@ZKO5A"&]
MZD.)&66\@F$9?8C[9NK#W)3:!]I)ID+ :&O'!&P.@ZSJ?VU#XJT>T*GV'6WL
MLL\U*W\_(M,9$ZDS)L7\X7Z@R.30X"WSVFO]X*J-W\A'7T'8?6*[5,I53H;-
MQ034. 3X"8-Z$R+.).97/_LV][S(E>J,/K_TE[?2
MWXP_W] &DB5A!KC389_#FXG/?5Z\G?9!2(PW)>_;1#!S8W1KJK@C#G1&IM71
M7FO%F@&(*8%I+>7;=WODA@KR;^J&C/RMF,?= GPIHS^\K7VLYPT-W< OOJ=
M$\NM8'\KBW-E<:J,)7:)D==8L;CH]J;]'_L.]S[K@;GH.Y"=C!
MCHBMSW$!VSN(!YC^FN'1(2N7!!C,@# ]S'4#>X>JCRF. ]>J20.ZW(O^@XT
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M;QPV@<V 'K80E>!KQ'O@@PS;YK7(U@>:3U>\@['1*[1HQ$*I95//IRU=K=
M Y/K@56UT4+WJ2)7'*PD<\FO>?(%K^ >D:$?N@[I,/(_(+NNE0,J=GRPODA+
M9\S+28V;-NHL81]VIS:@$%M_S0"WQSP&&(V_UP0\'/0XZ+>]F/<8]3'T"WOD
M2HSQP4,L+.G1A7J1_T 'I9V-YXPK[O3G,;^'^NX/?*EO%==.!M8]+HH.L%AB
M%"W=Y0/$%:$]75RLR\S!E$,(HM/$]_+DVL. /763T!3&W$,>
M8EWJW&M;R Y.&S.FGH1-\&0>:0>&$:+#;%TYB.L63()5)UWA#S3"*1"]K@S^
MI&?X@LWC\355^ PU,62K-L%D#Q@R64\4<2B(;AY[=ZU]Y>AJQ401H(,]"#2@"2:S0XFQ
M 0X6E6TB3;2'PV>?4!0C1!#%D4[4'_<28(-2^ RYZZ)PTWO*77U\AN .QAYZ
M> PY).B#QCD;Q_&:-%4W;$P^I^NW/I#K7U=-_::_07LS+%J-K\VS]B^W>-OL
M4SNJ=R^YZ=L!(SL)GD],8H\E4@5[6=LK)P0W9]-0:D>M#;.^;0^F >N%-AH:
MP$9KY\SZU.TF3E'7E77R8DFV1F7[VB^F4?K:[EBY&GSSXW
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M% ,4 " ":@W-0+M_;Q[@$ #I%@ $0 @ $ &UL4$L! A0#%
M @ FH-S4"^X$OT4!0 R"T !4 ( !7PP '-R<'0M,C R
M,# S,3A?<')E+GAM;%!+ 0(4 Q0 ( )J#
XML
8
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
JSON
9
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"srpt-8k_20200318.htm": {
"axisCustom": 0,
"axisStandard": 0,
"contextCount": 1,
"dts": {
"definitionLink": {
"remote": [
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
"http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
]
},
"inline": {
"local": [
"srpt-8k_20200318.htm"
]
},
"labelLink": {
"local": [
"srpt-20200318_lab.xml"
],
"remote": [
"https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
]
},
"presentationLink": {
"local": [
"srpt-20200318_pre.xml"
]
},
"referenceLink": {
"remote": [
"https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
]
},
"schema": {
"local": [
"srpt-20200318.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
"https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
"http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
"https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
"https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
]
}
},
"elementCount": 24,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2019-01-31": 2,
"total": 2
},
"keyCustom": 0,
"keyStandard": 95,
"memberCustom": 0,
"memberStandard": 0,
"nsprefix": "srpt",
"nsuri": "http://www.sareptatherapeutics.com/20200318",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "srpt-8k_20200318.htm",
"contextRef": "C_0000873303_20200318_20200318",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "100000 - Document - Document and Entity Information",
"role": "http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"body",
"html"
],
"baseRef": "srpt-8k_20200318.htm",
"contextRef": "C_0000873303_20200318_20200318",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 0,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address Address Line1",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address Address Line2",
"terseLabel": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address City Or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address State Or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation State Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r5"
],
"lang": {
"en-US": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_PreCommencementIssuerTenderOffer": {
"auth_ref": [
"r2"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
"label": "Pre Commencement Issuer Tender Offer",
"terseLabel": "Pre-commencement Issuer Tender Offer"
}
}
},
"localname": "PreCommencementIssuerTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_PreCommencementTenderOffer": {
"auth_ref": [
"r3"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
"label": "Pre Commencement Tender Offer",
"terseLabel": "Pre-commencement Tender Offer"
}
}
},
"localname": "PreCommencementTenderOffer",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r0"
],
"lang": {
"en-US": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Security12b Title",
"terseLabel": "Title of each class"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r1"
],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Name of each exchange on which registered"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_SolicitingMaterial": {
"auth_ref": [
"r4"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
"label": "Soliciting Material",
"terseLabel": "Soliciting Material"
}
}
},
"localname": "SolicitingMaterial",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-US": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"dei_WrittenCommunications": {
"auth_ref": [
"r6"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
"label": "Written Communications",
"terseLabel": "Written Communications"
}
}
},
"localname": "WrittenCommunications",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.sareptatherapeutics.com/20200318/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
}
},
"unitCount": 0
}
},
"std_ref": {
"r0": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r1": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r2": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "13e",
"Subsection": "4c"
},
"r3": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14d",
"Subsection": "2b"
},
"r4": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r6": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "425"
}
},
"version": "2.1"
}
EXCEL
10
Financial_Report.xlsx
IDEA: XBRL DOCUMENT
begin 644 Financial_Report.xlsx
M4$L#!!0 ( )J#X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$% @ FH-S4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04 " ":@W-0,@&ULS9+!2L0P$(9?17)O)VFA:.CVLN))07!!\1:2V=U@TX1DI-VWMXV[
M740?P&-F_GSS#4RK@]0^XG/T 2-93#>3ZX\4:O^/ 9^PPS&K!'
MAP,E$*4 UBT3PVGJ6[@"%AAA=.F[@&8EYNJ?V-P!=DY.R:ZI<1S+L0621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V!T3$LV4"P9!AI@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MSTS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0 ( )J#*LK ( /D+ 8 >&PO=V]R:W-H965T&UL=5;MCML@$'P5RP]P-MCYE!.IN:IJI5:*KNKU-TE(8ATV+I#X
M^O8%[',C=OEC Y[9 2\#6_52O>DKYR9Y;T2K-^G5F&Z=9?IXY0W33[+CK?UR
MEJIAQG;5)=.=XNSD28W(:)[/LX;5;;JM_-A>;2MY,Z)N^5XE^M8T3/W=<2'[
M34K2CX&7^G(U;B#;5AV[\)_<_.KVRO:R*RWM&9(WC$
M:\U[_=!.W%(.4KZYSK?3)LW=C+C@1^-",/NZ\VM_F579W84;$;D#0!P29$)F-/0E05(!Z
M>O% ISB]0.F%IY]"*8'T24N$")"I2 /@L$(&*."\Q0@1F@+P(!B%CB G-4
M8 [HJT (DB.*RQ0A07DDT "@43RO$0EEI ?)AI"(GE8H0HKJ% &"@ADADN0
M''=3#B/,0S\AF$5$)>)9 B,L0Q4$LXJHX,8E%$2@X&Q ,)'3@>#^)M"^E(8J
M"*:(J. F)]##-$P^AHEE'WKH,=S&&"7=Q]E"TN:+X!U.7NM7)01I;__DJ[2REX39>_F3C76T=/G4$/QO7
M7-BV&HK1H6-D-Q;:V53M;_\!4$L#!!0 ( )J#&POR_&9X[/CJ3&6U4K^K&&N
M:V6O>Z-1CVW+0IGK7FYM]<'SC,BAY&:@*U"466LLN:5'S#Q3(?#4Y "V++S0
M]R^]DDO5FTV-G$WM;*%%78*RC*N4W2@K[8[=J0."U&KJV=G4:TH/Y8\RI+E> +N&@'XPF5Q<=K22&QDKCW@7G++9$F6ED>P\B*:)39X3%
M30=8PK?L+B41Y%J*/6('JZMAWQ]?C<,P[$"*TA3!T,B-T<)XL^4R&+=##UK0.Y:Y5ET^
M"\>C_H@.1SO^!:6UH!H#E[3=#JXPCNJZD$+:QO"/I A*7K1+E@A]02! *AV6
M"RT-6D//Z[7+QBF^,Z:FXK_U)-+2*=)K!ESD3!3<.#2;(DXV,C39KAX5ZZT,UK\LDS:L6:=G&ULU55;B]4P$/XK(3_ G';9!:4MZ,*"H+*PY\'7
MM)VV@=Q,I\=V?[U)T]O1!_'@@[XT,]],OOERF33K<9+PT@$@&974?4X[1/N.
ML;[J0/'^C;&@?:0Q3G'TKFM9;QWPN@^3E&3IZ?3 %!>:%ID>U)/"GE1FT)C3
M$V5%UAB](WN]*Z32=.7D&?PF1Q3Y/
MUBML'9^2])[N$^;!%RF-J\%M91*Z0D4FH0ERG&B[,**Q+ 01C?)&+7AK-)\U
MK#,6P]-6(.5+.,*OS17WV)"8\[$.QT""BM7TJU[,>%S1"?Q'MLA]H+V_B998
M<3'X8?"KT;/_;3 (SPX:,<[^V&SU/3NW5D[OI6BU@KB6WQ9,;BQ89'RM0SKC
MQ*OG"S>E\@ X2B[@4%1'Y+OC]@PCKK=I;&[5G/Z'FO_V/K>@P7%Y%.VO_K^\
MRW^BF"W=>&%S.F7\/#*JS[9^]33(R_] W[%
M[^?6T/!!XG-8\1S,Z6Y_"B]-\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L#!!0
M ( )J#&PO=V]R:V)O;VLN>&ULC5'+;L(P
M$/P5RQ_0!-0B%1$NI0^DJD6EXNXD&[+"C\C>0,O7=^THA=YZLG=V/#L[7IR<
M/Y3.'<27T384LB7JYED6JA:,"C>N \N=QGFCB$N_ST+G0=6A!2"CLVF>SS*C
MT,KE8M3:^.RZ< 05H;,,1F"'< J7?BR%8L(1/E59R%P*U9-[0DW@5XK@V;N^
M0[LOY$2*!GV@;9R=F 8M&CQ#G:K0NM.+\WAVEI3>5MYIG5[%1GK$$\(OL@-/
M6/TADBH_%'LMY"QGP2,&+%$C?1MZV(LXL8M9X>?(
M#;^N)\GXZ+:&!BW4;SP@,,XA5!LOXI%TIK=WDWL.N]?Z@;%W^^I4TH\:X\ *A0V$LZ&8O:3RKC>LG^
MZ&JPLFAEC1"'X17FP?+)K=$U'AZS@>S'G10R/'1Y?
M,5'W])=9SUZ",*V'O\E$_37 ZM=E7U!+ P04 " ":@W-0"X_8 R$! !7
M! $P %M#;VYT96YT7U1Y<&5S72YX;6RU5$U/PS ,_2M3KVC-X, !;;L
M5Y@$?R D;ALU7[*]T?U[W&Y#8BIB:-LEB?/L]UX2*_/W;0::=,%'6A0-BVD1[1#K=$Y8(?LBAQF6ZD81B\MP)"\G>HA"4"G6"PG%A'TO=
MZP80G85_64M5Y0S89-9!2DK*"-I2 \#!E]1H!/O&Z&*]][O2R"\Z"+'JO/J1
M4%[/!V\]C!L8D$LJL[0%C$D-P&Z\/4OPT TF(4PS"HKL1HXGEE:"DNH3+WE$
MZ%O'@CU)7*BO]["?"=MA/7;AWR"I83KOUO]H=)G+H%W\S&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( )J#*LK (
M /D+ 8 " ?<( !X;"]W;W)K&PO&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" ":@W-0"X_8 R$! !7! $P @ 'E$@ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08 "@ * ( " W% !
end
XML
12
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
13
srpt-8k_20200318_htm.xml
IDEA: XBRL DOCUMENT
0000873303
2020-03-18
2020-03-18
false
0000873303
8-K
2020-03-18
Sarepta Therapeutics, Inc.
DE
001-14895
93-0797222
215 First Street
Suite 415
Cambridge
MA
02142
617
274-4000
false
false
false
false
Common Stock, Par Value $0.0001 per share
SRPT
NASDAQ
false
|